Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

An experimental male contraceptive pill could soon enable men to prevent pregnancy on demand as researchers are aiming for it to work within 30 minutes of being ingested and provide protection for at least six to eight hours.

Scientists at Weill Cornell Medicine in the United States have received a grant of $8.2 million from the National Institutes of Health to test the drug in a human trial for the first time. The investigational pill is designed to temporarily stop the sperm in its tracks, rather than suppressing hormone production or formation of sperm.

The drug’s effectiveness, safety and ability to maintain fertility health after each dose remain to be investigated.

More About The Experimental Male Contraceptive Pill

Researchers Dr Jochen Buck and Dr Lonny Levin, professors of pharmacology at Weill Cornell, are developing a compound that blocks an enzyme called soluble adenylyl cyclase (sAC).

This enzyme plays a crucial role in sperm motility, the ability of sperm to move. By inhibiting sAC, the drug is intended to temporarily immobilise sperm, preventing them from swimming enough to fertilise an egg.

In 2023, the researchers reported in Nature Communications that blocking sAC rendered sperm immobile and prevented pregnancies in preclinical models. This drug differs from experimental hormonal male contraceptives, which generally aim to reduce sperm production and may require weeks to become effective.

“We’ve developed an on-demand contraceptive pill that men would take 30 minutes before having sex,” Buck said in a statement from Weill Cornell Medicine. “The pill provides a six-to-eight-hour window of protection from pregnancy, and afterwards, fertility returns to normal.”

These timings reflect the researchers’ intended profile for the drug. They have not yet been confirmed in people yet.

Also read: 'Contraceptive Coil Saved My Life': UK Woman's Persistent Abdominal Pain Led Her To Ovarian Cancer Diagnosis

Humans Trials Planned

The four-year grant will fund the toxicology and safety studies that are needed before human testing. The grant will also cover the development of an oral formulation as well as the drug’s manufacturing processes.

The next step is a Phase 1, placebo-controlled trial in which healthy men will participate. Researchers will monitor participants for side effects and examine sperm samples to measure changes in motility. They will also investigate whether the effect is temporary and sperm movement returns to normal after the drug’s effect wears off.

“Contraception is unusual in that you’re giving a medicine to healthy people, often in their prime, so the requirements for efficacy and safety are particularly stringent,” said Dr Peter Meinke, an assistant professor of pharmacology at Weill Cornell who has contributed to the drug's development.

“You need a molecule that is fast-acting, potent, safe and which is active for hours in the male but also continues to prevent sperm from swimming inside the drug-free female,” he added.

Also read: What Does A Morning-After Pill Do To Your Body?

Could It Be A Breakthrough In Male Contraception?

Male contraceptive options that are currently available include just condoms and vasectomy. Other experimental methods include hormonal pills, gels and long-acting treatments. Many require regular use and can take weeks to affect fertility.

An on-demand pill could offer an instant method for preventing unwanted pregnancy by allowing men to use the drug around the time they have sex, provided the future trials prove it is safe and effective.

“I hope someday family planning becomes a shared responsibility where men or couples can go to the local pharmacy to get male contraceptives,” Levin said. “This gives couples another option to discuss what is best for them.”

US President Donald Trump’s former daughter-in-law Vanessa Trump recently revealed that she is now cancer-free.

The former wife of Donald Trump Jr also shared the early signs of the disease she experienced before getting diagnosed. The 48-year-old is now undergoing surgery and radiation.

Vanessa Trump Reveals Early Signs Before Breast Cancer Diagnosis

In an interview with her daughter, Kai Trump and radiologist Dr Nicole Saphier for Breast Cancer Awareness Month, Vanessa said that she was unusually exhausted for months before getting diagnosed in April 2026. She said that even normal activities in her routine would leave her spent.

“I would love to go and get my Starbucks, and then two hours later, I would feel exhausted,” she said.

Vanessa also said she experienced constant arm pain for several months before noticing something in her left breast

She was diagnosed with invasive ductal carcinoma, a common form of breast cancer in which cancer cells surface in the milk ducts and spread into breast tissue.

Vanessa underwent a lumpectomy to remove the tumour, followed by three courses of radiation treatment. In an update shared in October, she said a recent breast MRI came back clear. “I'm finally cancer-free,” she said.

Vanessa shared that she will need regular scans in the coming years to monitor her health.

Also read: Jessie J 'Healing' After 2nd Breast Reconstruction Surgery: Why Some Patients Need Multiple Procedures

Is Extreme Fatigue An Early Sign Of Breast Cancer?

Fatigue is a symptom of various health conditions, but it can also occur in people with cancer. Fatigue related to cancer may feel more intense than normal tiredness and may not improve with adequate sleep or rest.

However, just fatigue is not a reliable sign of breast cancer. It can be due to various other causes like anaemia, thyroid disorders, sleep problems, infections, stress and other medical conditions.

Vanessa's diagnosis puts focus on the importance of paying attention to unusual changes in the body, especially when they occur alongside other symptoms.

Also read: Breast Cancer Awareness Day: Experts Explain Most Overlooked Breast Changes That Can Delay Diagnosis In Men

Breast Cancer Symptoms That Should Not Be Ignored

Breast cancer does not present in the same way in everyone. Some people may notice a lump, while others experience changes in the breast or surrounding areas like armpits or arms. Warning signs of breast cancer include:

• New lump or thickening sensation: A lump in the breast or underarm that feels different from the surrounding tissue.
• Changes in breast size or shape: Newfound edema or a change in appearance of the breast is also a sign.
• Changes in skin: Dimpling, puckering, redness or skin that resembles the texture of an orange peel.
• Nipple changes: A newly inverted nipple, unusual discharge, or changes in the skin around the nipple.
• Stubborn pain: Ongoing pain in the breast or underarm that is unusual for the individual.
• Arm pain: Arm pain is not a typical breast cancer symptom. But unexplained pain, especially accompanied with changes in breast, warrants medical assessment.

Dr Saphier emphasised that breast cancer can present differently from one person to another. “When it comes to breast cancer, it's not one size fits all. It feels different for everyone,” she said.

A person should not wait for a lump to become large or painful. Anyone who notices a new breast lump, nipple change, or changes in skin should consult a healthcare professional.

Screening mammograms can help detect breast cancer before symptoms appear, but the appropriate screening schedule depends on age, risk and local guidelines. prioritise their health and seek timely checks.

Heart disease is the leading cause of death among women, yet sex-specific cardiovascular risks often go unrecognized.

Four medical societies — the American Heart Association, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine — have issued new guidance to help clinicians identify these risks early and improve heart health in women and girls.

The guidance highlights heavy periods, irregular menstrual cycles and pregnancy complications as potential indicators of cardiovascular risk. It also introduces a “Female Life Stages” framework to guide prevention from puberty through menopause and beyond.

“Women experience their health care across clinical specialties, but it often is fragmented or disconnected,” said Sadiya S. Khan, chair of the collaborative writing group and professor of cardiovascular epidemiology at Northwestern University Feinberg School of Medicine in Chicago.

What Does The New Guidance Include?

Also read: This Common Heart Attack Risk Starts Silently In Healthy People In Their 20s

Progress in preventing cardiovascular deaths among women has stalled over the past two decades. The new framework identifies four life stages as opportunities for early risk detection and prevention.

• Perimenarche (ages 8–15): The transition around the first menstrual period.
• Ovarian cycling (ages 15–44): The stage when regular ovulatory and hormonal cycles are established.
• Perimenopause (ages 45–51): The transition marked by irregular cycles and hormonal changes.
• Postmenopause (age 51 onward): The years after menopause, defined as 12 months after the final menstrual period.

Pregnancy, at any stage, is also described as a biological “stress test” that can reveal previously unrecognized cardiovascular risks.

Women's Heart Risks: Heavy Periods And Irregular Cycles

The guidance recognizes menstrual patterns as a female-specific vital sign. Heavy or irregular bleeding may indicate cardiovascular risk, including risks associated with polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome (PCOS).

Women's Heart Risks: Perimenopause And Postmenopause

Read More: 100% Blockage At 18, 25% Patients Under 40: On World Heart Day, Cardiologists Reveal An Alarming Heart Attack Pattern

Changes in cholesterol and metabolic health during perimenopause may signal rising cardiovascular risk. Early identification and preventive action may help reduce future risk.

The years after menopause can also account for up to 40% of a woman’s lifetime. Most heart attacks, strokes and heart failure events occur during this stage, according to the guidance. More than 80% of these events are considered preventable through early action.

Women's Heart Risks: Pregnancy Complications And Mental Health

Anxiety, depression and eating disorders can contribute to poorer cardiovascular health. The framework urges clinicians to consider psychosocial factors alongside hormonal and cardiovascular health.

High blood pressure, preeclampsia, gestational diabetes, preterm birth, small-for-gestational-age infants and stillbirth are recognized as female-specific cardiovascular risk enhancers.

The 2026 American Heart Association/American College of Cardiology cholesterol guideline also includes pregnancy-related factors in cardiovascular risk assessment.

Only about 60% of U.S. women with high blood pressure-related pregnancy complications receive follow-up care for their blood pressure within six months of delivery. The collaborating societies are calling for action to close this gap and ensure cardiovascular risks identified during pregnancy receive continued attention.

Need For Dedicated Women's Heart Care Centers

The societies propose a national network of Comprehensive Centers of Excellence for Women’s Cardiovascular Care, focused on clinical care, professional education, research and community engagement.

They also call for greater inclusion of women in research, increased funding for women’s health and better translation of evidence into clinical practice.